# EDGAR Filing Document

**Accession Number:** 0001776985
**File Stem:** 0001193125-25-246843
**Filing Date:** 2025-10
**Character Count:** 6560
**Document Hash:** 1db1510e13fef08ad29d69637bed1f82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-246843.hdr.sgml**: 20251022

**ACCESSION NUMBER**: 0001193125-25-246843

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251022

**DATE AS OF CHANGE**: 20251022

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CureVac N.V.
- **CENTRAL INDEX KEY:** 0001809122
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91630
- **FILM NUMBER:** 251410436

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076
- **BUSINESS PHONE:** 49 7071 9883 0

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CureVac B.V.
- **DATE OF NAME CHANGE:** 20200410
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioNTech SE
- **CENTRAL INDEX KEY:** 0001776985
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131
- **BUSINESS PHONE:** 0049613190840

**MAIL ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)** 

**of the Securities Exchange Act of 1934** 

**(Rule 14d-100)** 

**(Amendment No. 1)** 

## CureVac N.V.
**(Name of Subject Company (Issuer))** 

**BioNTech SE** 

**(Name of Filing Person (Offeror))** 

**Common Shares, €0.12 par value per share** 

**(Title of Class of Securities)** 

**N2451R105** 

**(CUSIP Number of Class of Securities)** 

**Prof. Ugur Sahin, M.D.** 

**An der Goldgrube 12** 

**D-55131 Mainz** 

**Germany** 

**Telephone: +49 6131-9084-0** 

**(Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)** 

***with copies to:***

---

| | |
|:---|:---|
| **Paul Claydon**<br> **Jack S. Bodner**<br> **Matthew T. Gehl**<br> **Charles A. Dobb**<br> **Brian K. Rosenzweig**<br> **Covington & Burling LLP**<br> **30 Hudson Yards**<br> **New York, New York 10001-2170**<br> **Telephone: (212) 841-1000** | **Howard L. Ellin**<br> **June S. Dipchand**<br> **Stephan Hutter**<br> **Holger Hofmeister**<br> **Skadden, Arps, Slate, Meagher & Flom LLP**<br> **One Manhattan West**<br> **395 Ninth Avenue**<br> **New York, New York 10001**<br> **Telephone: (212) 735-3000** |

---

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

This Amendment No. 1 amends and supplements the Tender Offer Statement on Schedule TO filed by BioNTech SE, a European stock corporation (*Societas Europaea*, or SE) organized under the laws of Germany and the European Union ("*BioNTech*"), on October 21, 2025 (the "*Schedule TO*"). The Schedule TO relates to the offer by BioNTech to exchange American Depositary Shares, each representing one ordinary share, no par value, with a notional amount attributable to each ordinary share of €1, of BioNTech, for all of the outstanding ordinary shares, par value €0.12 per share, of CureVac N.V., a public limited liability company (*naamloze vennootschap*) incorporated under the laws of the Netherlands, upon the terms and subject to the conditions set forth in the Exchange Offer Prospectus and the related Letter of Transmittal, each as defined in the Schedule TO. The Exchange Offer Prospectus and Letter of Transmittal are incorporated by reference to Exhibit (a)(1)(A) and (a)(4) of the Schedule TO.

The information set forth in the Exchange Offer Prospectus, including all annexes thereto, is hereby expressly incorporated by reference in response to all of the items of the Schedule TO, and is supplemented by the information specifically provided herein.

**Item 12. Exhibits.** 

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| (a)(5)(K) | [Press Release issued by BioNTech SE, dated October 22, 2025 (incorporated by reference to Exhibit 99.1 to the Report on Form 6-K filed by BioNTech SE with the SEC on October 22, 2025).](http://www.sec.gov/Archives/edgar/data/1776985/000119312525246740/d42810dex991.htm) |
| (a)(5)(L) | [BioNTech SE Social Media Post (LinkedIn), dated October 22, 2025 (incorporated by reference to BioNTech's filing with the SEC pursuant to Rule 425 on October 22, 2025).](http://www.sec.gov/Archives/edgar/data/1809122/000119312525246761/d941455d425.htm) |

---

------

**SIGNATURES** 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
|  Dated: October 22, 2025 | Dated: October 22, 2025 |
|  BioNTech SE | BioNTech SE |
|  By: | /s/ Prof. Ugur Sahin, M.D. |
|  | Name: Prof. Ugur Sahin, M.D. |
|  | Title: Chief Executive Offer |

---